Clinical Trial Update: HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor [Phase 4]

View source ↗

Summary

Phase 4 trial update for HemLibra prophylaxis in patients with haemophilic pseudotumor has been terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilic Pseudotumour

Drugs mentioned

• Hemlibra (emicizumab)

Snippet

Sponsor: Indiana Hemophilia &Thrombosis Center, Inc. | Conditions: Haemophilic Pseudotumour | Phase 4 | Status: TERMINATED | Results posted: 2024-03-20